尿激酶和硫酸镁联合治疗急性脑梗死的临床研究

目的评价尿激酶和硫酸镁联合治疗急性脑梗死（发病6h内）的疗效及其安全性。方法 凡符合入选标准的病人60例随机分为治疗组和对照组，治疗组应脂尿激酶和硫酸镁治疗，对照组应用尿激酶治疗，评价治疗前及治疗后24h、7d、14d、28d、90d的神经功能缺损评分和90d后疗效。结果（1）治疗后7d、14d、28d、90d时治疗组神经功能缺损与对照组比较有显著差异（P〈0．05）。（2）治疗90d后治疗组显效率和基本痊愈率与对照绀比较有差异（P〈0．05），（3）治疗组不良反应发生率低于对照组（P〈0．05）。结论静脉内联合应用尿激酶和硫酸镁比单用尿激酶溶栓治疗效果好。

Clinical research on the combined treatment of urokinase and magnesium sulfate for acute cerebral infarction

Objective To evaluate the efficacy and safety of combined treatment of acute cerebral infarction with urokinase and magnesium sulfate (onset time <6 h). Methods All 60 patients meeting the criteria were divided randomly into combined treatment group and control group. The former was treated with urokinase and magnesium sulfate while the latter was treated with urokinase alone. The scores of neurologic impairment were recorded before and after the treatment at different intervals (24 h, 7 d, 14 d, 28 d, 90 d). The curative effects were evaluated at the 90 d. Results There was a singnicant improvement in the score of neurologic impairment at 7 d, 14 d, 28 d after the treatment in the subject group, compared with those in the control (P<0.05). There was no statistical difference in the total effictive rate between the two groups. But the combined treatment group had a significantly higher excellence rate and healing rate, lower adverse effect rate, compared with the control (P<0.01, P<0.05, P<0.05, respectively). Conclusion Therapy of acute cerebral infarction by combined treatment with urokinase and magnesium sulfate via intravenous injection is more effective and safe than the use of urokinase alone.